(Total Views: 540)
Posted On: 08/21/2021 12:39:03 AM
Post# of 154778
Regeneron and Lilly's MAB are "spike targeting" MABs.. they bind to the spike protein of the virus from last year and alert the immune system that there's an invader.
It will work well when given early in Covid infection for people with a variant that's similar to wild type / last year's.. people who are turned away from care until "they get worse" won't benefit as much. People who are infected with a variant with a mutated spike protein won't benefit as much. As time goes by, these Spike MABs will eventually, effectively, stop working.
It will work well when given early in Covid infection for people with a variant that's similar to wild type / last year's.. people who are turned away from care until "they get worse" won't benefit as much. People who are infected with a variant with a mutated spike protein won't benefit as much. As time goes by, these Spike MABs will eventually, effectively, stop working.
Quote:
The US government is no longer distributing Eli Lilly's bamlanivimab into California, Arizona and Nevada because of the prevalence of a viral variant that is not susceptible to the monoclonal antibody, FDA acting commissioner Janet Woodcock told physicians taking part in a webinar with the American Medical Association ...Mar 17, 2021
(2)
(0)
